Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Net revenue:
Total net revenue	[1]	$ 99,548	$ 103,221	$ 287,951	$ 301,368
Cost of revenue:
Total cost of revenue	[2]	60,415	62,755	177,975	184,643
Gross profit		39,133	40,466	109,976	116,725
Operating expenses:
Research and development		11,164	12,913	37,569	40,442
Selling and marketing		11,106	12,903	35,699	41,078
General and administrative		8,894	11,769	29,396	37,880
Total operating expenses		31,164	37,585	102,664	119,400
Income (loss) from operations		7,969	2,881	7,312	(2,675)
Gain (loss) on equity method investment, net		222		222
Other income (expense), net		(5,281)	(3,829)	(1,954)	(11,133)
Income (loss) before provision for income taxes		2,910	(948)	5,580	(13,808)
Provision for income taxes		285	236	1,601	1,222
Net income (loss)		$ 2,625	$ (1,184)	$ 3,979	$ (15,030)
Net income (loss) per share - basic		$ 0.03	$ (0.01)	$ 0.04	$ (0.17)
Net income (loss) per share - diluted		$ 0.03	$ (0.01)	$ 0.04	$ (0.17)
Weighted average common shares used in computing net income (loss) per share:
Basic		90,476	87,962	89,585	87,220
Diluted		90,855	87,962	90,429	87,220
Net income (loss)		$ 2,625	$ (1,184)	$ 3,979	$ (15,030)
Foreign currency translation adjustment		(628)	(270)	(769)	(604)
Comprehensive income (loss)		1,997	(1,454)	3,210	(15,634)
Products
Net revenue:
Total net revenue		45,527	46,451	126,892	136,019
Cost of revenue:
Total cost of revenue		27,573	27,169	73,661	80,755
Services
Net revenue:
Total net revenue		54,021	56,770	161,059	165,349
Cost of revenue:
Total cost of revenue		$ 32,842	$ 35,586	$ 104,314	$ 103,888

[1] Includes sales to the China joint venture, an equity method investment of $6,145 and $12,605 for the three and nine months ended March 31, 2020 and $0 for both the three and nine months ended March 31, 2019, respectively. See Note 14.

[2] Includes cost of revenue from sales to the China joint venture, an equity method investment of $4,350 and $8,980 for the three and nine months ended March 31, 2020 and $0 for both the three and nine months ended March 31, 2019, respectively. See Note 14.